Corpovael - Public Comps and Valuation Multiples

Corpovael Overview

About Corpovael

Corpovael SA de CV is engaged in developing, building and commercializing accessible housing for the middle and lower level of the Mexicans. The company seeks new investment alternatives in other States of the Republic in order to provide a home for more Mexicans.

Founded

2007

HQ

Employees

n/a

Website

caduinmobiliaria.com

Sectors

Real Estate Development

Financials

LTM Revenue $249M

LTM EBITDA $41.3M

EV

$155M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Corpovael Financials

As of September 2025, Corpovael reported last 12-month revenue of $249M and EBITDA of $41.3M.

In the same period, Corpovael generated $71.1M in LTM gross profit and $13.8M in net income.

See Corpovael valuation multiples based on analyst estimates

Corpovael P&L

In the most recent fiscal year, Corpovael reported revenue of $243M and EBITDA of $25.7M.

Corpovael expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Corpovael valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$249M	XXX	$243M	XXX	XXX	XXX
Gross Profit	$71.1M	XXX	$64.8M	XXX	XXX	XXX
Gross Margin	29%	XXX	27%	XXX	XXX	XXX
EBITDA	$41.3M	XXX	$25.7M	XXX	XXX	XXX
EBITDA Margin	17%	XXX	11%	XXX	XXX	XXX
EBIT	$24.2M	XXX	$23.5M	XXX	XXX	XXX
EBIT Margin	10%	XXX	10%	XXX	XXX	XXX
Net Profit	$13.8M	XXX	$12.5M	XXX	XXX	XXX
Net Margin	6%	XXX	5%	XXX	XXX	XXX
Net Debt	XXX	XXX	$93.3M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Corpovael including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $249M. EBITDA for the last twelve months was $41.3M. In the most recent fiscal year, Corpovael achieved $243M in revenue and $25.7M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$249M	Analyst estimates available to subscribers	$243M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$71.1M	Analyst estimates available to subscribers	$64.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	28.5% gross margin	Analyst estimates available to subscribers	26.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$41.3M	Analyst estimates available to subscribers	$25.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	16.6% EBITDA margin	Analyst estimates available to subscribers	10.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$24.2M	Analyst estimates available to subscribers	$23.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	9.7% EBIT margin	Analyst estimates available to subscribers	9.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$13.8M	Analyst estimates available to subscribers	$12.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	5.5% net profit margin	Analyst estimates available to subscribers	5.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$93.3M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Corpovael

This financial data table provides comprehensive performance metrics for Corpovael, a company based in Mexico. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Corpovael generated $249M in revenue over the last twelve months.
The company achieved $41.3M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $71.1M.
Net income over the last twelve months reached $13.8M.

Fiscal Year Performance

In the most recent fiscal year, Corpovael reported $243M in total revenue.
Fiscal year EBITDA was $25.7M.
The company maintained a gross profit margin of 26.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 10.6%.
Net profit margin reached 5.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Corpovael. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Corpovael Stock Performance

Corpovael has current market cap of MXN 989M (or $53.5M), and EV of MXN 2.9B (or $155M).

Market Cap Evolution

Corpovael Stock Data

As of October 2, 2025, Corpovael's stock price is MXN 3 (or $0).

See Corpovael trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$155M	$53.5M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Corpovael Valuation Multiples

Corpovael's trades at 0.6x EV/Revenue multiple, and 6.0x EV/EBITDA.

See valuation multiples for Corpovael and 15K+ public comps

Corpovael Financial Valuation Multiples

As of October 2, 2025, Corpovael has market cap of $53.5M and EV of $155M.

Equity research analysts estimate Corpovael's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Corpovael has a P/E ratio of 3.9x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$53.5M	XXX	$53.5M	XXX	XXX	XXX
EV (current)	$155M	XXX	$155M	XXX	XXX	XXX
EV/Revenue	0.6x	XXX	0.6x	XXX	XXX	XXX
EV/EBITDA	3.8x	XXX	6.0x	XXX	XXX	XXX
EV/EBIT	6.4x	XXX	6.6x	XXX	XXX	XXX
EV/Gross Profit	2.2x	XXX	n/a	XXX	XXX	XXX
P/E	3.9x	XXX	4.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	15.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Corpovael Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Corpovael Margins & Growth Rates

Corpovael's last 12 month revenue growth is 1%

Corpovael's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Corpovael's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Corpovael's rule of X is 19% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Corpovael and other 15K+ public comps

Corpovael Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	1%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	17%	XXX	11%	XXX	XXX	XXX
EBITDA Growth	2%	XXX	17%	XXX	XXX	XXX
Rule of 40	13%	XXX	11%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	19%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	17%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial